Meeting
2022 ASCO Annual Meeting
Phase I study of epacadostat in combination with sirolimus in advanced malignancy.
Authors
Chao Hui Huang
University of Kansas Medical Center, Westwood, KS
Chao Hui Huang , Takefumi Komiya , Anup Kasi , Stephen K. Williamson , Joaquina Celebre Baranda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03217669
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2575)
DOI
10.1200/JCO.2022.40.16_suppl.2575
Abstract #
2575
Poster Bd #
230
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
First Author: Gregory Lawrence Beatty
Poster
2013 ASCO Annual Meeting
A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors.
First Author: Devalingam Mahalingam